Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?

Neuropediatrics

Volumn 38, Issue 2, 2007, Pages 83-87

  Schmitt, Bernhard ^a   Kovacevic Preradovic, T ^a   Critelli, H ^a   Molinari, L ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Absence epilepsy; Children; Ethosuximide; Tonic clonic epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; PHENOBARBITAL; VALPROIC ACID;

ABSENCE; ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; FAMILY HISTORY; FEMALE; GRAND MAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RISK FACTOR; SPIKE WAVE; THERAPY DELAY;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; EPILEPSY, TONIC-CLONIC; ETHOSUXIMIDE; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 34548753477     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984446     Document Type: Article

References (34)

1. Bartolomei F, Roger J, Bureau M, Genton P, Dravet C, Viallat D et al. Prognostic factors for childhood and juvenile absence epilepsies. Eur Neurol 1997; 37: 169-175
2. Baykan B, Matur Z, Gurses C, Aykutlu E, Gokyigit A. Typical absence seizures triggered by photosensitivity. Epilepsia 2005; 46: 159-163
3. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia 2001; 42: 1553-1562
4. Berkovic SF. Childhood absence epilepsy and juvenile absence epilepsy. In: Wyllie E (Eds), The treatment of epilepsy Principles and practice. Philadelphia London: Lea & Febiger, 1993; 547-551
5. Browne TR, Dreifuss FE, Dyken PR, Goode DJ, Penry JK, Porter RJ et al. Ethosuximide in the treatment of absence (peptit mal) seizures. Neurology 1975; 25: 515-524
6. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999; 21: 303-306
7. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004; 45: 1049-1053
8. Covanis A, Skiadas K, Loli N, Lada C, Theodorou V. Absence epilepsy: early prognostic signs. Seizure 1992; 1: 281-289
9. Dieterich E, Baier WK, Doose H, Tuxhorn I, Fichsel H. Longterm follow-up of childhood epilepsy with absences. I. Epilepsy with absences at onset. Neuropediatrics 1985; 16: 149-154
10. Dieterich E, Doose H, Baier WK, Fichsel H. Longterm follow-up of childhood epilepsy with absences. II. Absence-epilepsy with initial grand mal. Neuropediatrics 1985; 16: 155-158
11. Doose H. Epilepsien im Kindes- und Jugendalter [Epilepsies in childhood and adolescence]. Hamburg: Desitin Arzneimittel GmbH, 1998
12. Eeg-Olofsson O, Petersen I, Sellden U. The development of the electroencephalogram in normal children from the age of 1 through 15 years. Paroxysmal activity. Neuropaediatrie 1971; 2: 375-404
13. Fisher RS, Harding G, Erba G, Barkley GL, Wilkins A. Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group. Epilepsia 2005; 46: 1426-1441
14. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999; 40: 973-979
15. Friedel B, Lempp R. Grand-mal-Provokation bei der Behandlung kindlicher petit-mal mit Oxazolidinen oder Succinimiden und ihre therapeutischen Konsequenzen [Grand mal provocation in the treatment of petit mal in children with oxazolidines or succinimides and its therapeutic consequences]. Z Kinderheilkd 1962; 87: 42-51
16. Glauser TA. Succinimides Adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Antiepileptic Drugs 5th edn., Philadelphia Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams & Wilkins, 2002; 658-664
17. Gordon N. Treatment of epilepsy with alpha-ethyl-alpha-methyl- succinimide (P.M. 671). Neurology 1961; 11: 266-268
18. Grosso S, Galimberti D, Vezzosi P, Farnetani M, Bartolo RM Di, Bazzotti S et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia 2005; 46: 1796-1801
19. Guiwer J, Valenti MP, Bourazza A, Hirsch E. Loiseau P Prognosis of idiopathic absence epilepsies In: Jallon P (Ed), Prognosis of epilepsies. Paris: John Libbey Eurotext, 2003; 249-257
20. Hedstrom A, Olsson I. Epidemiology of absence epilepsy: EEG findings and their predictive value. Pediatr Neurol 1991; 7: 100-104
21. ILAE CoCaTot. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30: 389-399
22. Jeavons PM. Harding GFA Photosensitive epilepsy. London Philadelphia: Spastics International Medical Publications, 1975
23. Loiseau P, Duche B, Pedespan JM. Absence epilepsies. Epilepsia 1995; 36: 1182-1186
24. Lorentzdehaas AM, Kuilman M. Ethosuximide (alpha-ethyl-alpha- methylsuccinimide) and grand mal. Epilepsia 1964; 23: 90-96
25. Olsson I. Epidemiology of absence epilepsy. I. Concept and incidence. Acta Paediatr Scand 1988; 77: 860-866
26. Panayiotopoulos CP. Typical absence seizures and their treatment. Arch Dis Child 1999; 81: 351-355
27. Pearl PL, Holmes GL. Absence seizures. In: Pellock JM, Dodson WE, Bourgeois BFD (Eds), Pediatric epilepsy. New York: Demos, 2004; 219-231
28. Posner EB, Mohamed K, Marson AG. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2003; CD003032
29. Todorov AB, Lenn NJ, Gabor AJ. Exacerbation of generalized nonconvulsive seizures with ethosuximide therapy. Arch Neurol 1978; 35: 389-391
30. Waltz S, Christen HJ, Doose H. The different patterns of the photoparoxysmal response - a genetic study. Electroencephalogr Clin Neurophysiol 1992; 83: 138-145
31. Wirrell E, Cornfield C, Camfield P, Dooley J. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. Epilepsia 2001; 42: 760-763
32. Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996; 47: 912-918
33. Wolf P, Goosses R. Relation of photosensitivity to epileptic syndromes. J Neurol Neurosurg Psychiatry 1986; 49: 1386-1391
34. Wolf P, Inoue Y. Therapeutic response of absence seizures in patients of an epilepsy clinic for adolescents and adults. J Neurol 1984; 231: 225-229